Phosphorylated α-synuclein in Parkinson's disease.

Science Translational Medicine
Yu WangJing Zhang

Abstract

Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total α-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

References

Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·W R Gibb, A J Lees
Aug 28, 1997·Nature·M G SpillantiniM Goedert
May 1, 1999·Journal of the Neurological Sciences·S GilmanG K Wenning
Jan 29, 2002·Nature Cell Biology·Hideo FujiwaraTakeshi Iwatsubo
Jun 10, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Wanli W SmithChristopher A Ross
Aug 26, 2006·Biochemical and Biophysical Research Communications·Takahiko TokudaOmar M A El-Agnaf
Apr 7, 2007·Journal of Neuropathology and Experimental Neurology·Irene LitvanDonald L Price
Oct 2, 2007·Biochemical and Biophysical Research Communications·Hiroaki SasakawaKoichi Kato
Jan 8, 2008·Proceedings of the National Academy of Sciences of the United States of America·Oleg S GorbatyukNicholas Muzyczka
May 3, 2008·Journal of Neuropathology and Experimental Neurology·Elisa A Waxman, Benoit I Giasson
Aug 2, 2008·Proceedings of the National Academy of Sciences of the United States of America·Clemens R ScherzerMichael G Schlossmacher
Mar 11, 2009·Antioxidants & Redox Signaling·Saurabh Sen, Andrew B West
Feb 17, 2010·Brain : a Journal of Neurology·Zhen HongJing Zhang
Jul 6, 2010·The European Journal of Neuroscience·Federica AgostaMassimo Filippi
Jul 9, 2010·Current Opinion in Neurology·Dennis W DicksonKeith A Josephs
Dec 29, 2010·Frontiers in Neurology·Athena L ChenR John Leigh
Jan 6, 2011·Journal of Neural Transmission·Karin SrulijesWalter Maetzler
Feb 26, 2011·Brain : a Journal of Neurology·Ivana DevicJing Zhang
Mar 15, 2011·Annals of Neurology·Min ShiJing Zhang

❮ Previous
Next ❯

Citations

May 30, 2013·Journal of Neural Transmission·Philipp Mahlknecht, Werner Poewe
Nov 23, 2013·Parkinsonism & Related Disorders·Kelvin C Luk, Virginia M-Y Lee
Aug 1, 2013·Nature Reviews. Neuroscience·David J IrwinJohn Q Trojanowski
Nov 8, 2012·International Journal of Alzheimer's Disease·Michela Deleidi, Walter Maetzler
Dec 4, 2012·Journal of Cell Science·Byung Rho LeeTetsu Kamitani
Sep 18, 2013·Proceedings of the National Academy of Sciences of the United States of America·Mahmood Haj-YahyaAshraf Brik
Nov 15, 2012·Neuroscience Letters·Brit MollenhauerMichael G Schlossmacher
Feb 1, 2015·Acta Neuropathologica Communications·Tessandra StewartJing Zhang
Nov 27, 2014·Frontiers in Cellular Neuroscience·Félix J Jiménez-JiménezJosé A G Agúndez
Dec 17, 2014·Nature Reviews. Neurology·Alberto LleóBrit Mollenhauer
Jul 6, 2016·The EPMA Journal·Jiri PolivkaOndrej Topolcan
May 18, 2016·Scientific Reports·Steffen HalbgebauerMarkus Otto
Jul 22, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ju-Hee KangUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 15, 2015·Neurobiology of Disease·Dominik BrückLisa Fellner
Sep 13, 2014·Neurobiology of Aging·Chandana BuddhalaPaul T Kotzbauer
Aug 24, 2013·Molecular & Cellular Proteomics : MCP·Adrien W SchmidHilal A Lashuel
Jun 13, 2017·Expert Review of Molecular Diagnostics·Lucia FarottiLucilla Parnetti
May 7, 2014·Marine Drugs·Clara GrossoPaula B Andrade
Apr 12, 2017·Brain : a Journal of Neurology·Hugo Vicente MirandaTiago F Outeiro
Sep 8, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Paolo EusebiLucilla Parnetti
Oct 28, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Piotr LewczukUNKNOWN Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato
Jan 16, 2018·Parkinson's Disease·Juan Antonio Castillo-GonzalezHumberto Rodriguez-Rocha
Oct 13, 2017·Expert Review of Neurotherapeutics·Kurt A Jellinger
Oct 10, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Kurt A Jellinger
Sep 27, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Wataru SakoRyuji Kaji
Oct 12, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Zhan-Fang SunHong Jiang
Nov 16, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Inger van SteenovenOmar M A El-Agnaf
Jul 3, 2019·Journal of Neurochemistry·Muneera FayyadOmar M A El-Agnaf
Jan 25, 2013·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Takashi Kasai, Takahiko Tokuda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.